← Back to Screener
Jupiter Neurosciences, Inc. Common Stock (JUNS)
Price$0.24
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-88.16%
Price vs S&P 500 (4W)-27.24%
VGM Score20.25
Market Capitalization$10.51M
All Metrics
Book Value / Share (Quarterly)$0.00
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-67.55%
Cash Flow / Share (Quarterly)$-0.16
Price vs S&P 500 (YTD)-84.42%
Net Profit Margin (TTM)-11463.51%
EPS (TTM)$-0.26
10-Day Avg Trading Volume5.53M
EPS Excl Extra (TTM)$-0.26
EPS (Annual)$-0.25
ROI (Annual)-56.50%
Gross Margin (Annual)80.60%
Cash / Share (Quarterly)$0.07
ROA (Last FY)-155.37%
EBITD / Share (TTM)$-0.27
Operating Margin (TTM)-11796.74%
Cash Flow / Share (Annual)$-0.16
P/B Ratio183.09x
P/B Ratio (Quarterly)1067.68x
Net Income / Employee (Annual)$-1,729,000
Net Interest Coverage (TTM)-67.83x
ROA (TTM)-228.64%
EPS Incl Extra (Annual)$-0.25
Current Ratio (Annual)0.65x
Quick Ratio (Quarterly)0.48x
3-Month Avg Trading Volume4.32M
52-Week Price Return-70.76%
Revenue / Employee (TTM)$8,100
Tangible BV / Share (Quarterly)$-0.24
P/S Ratio (Annual)482.25x
Asset Turnover (Annual)0.00x
52-Week High$3.33
EPS Excl Extra (Annual)$-0.25
26-Week Price Return-80.24%
Quick Ratio (Annual)0.63x
13-Week Price Return-42.36%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)0.51x
Enterprise Value$12.97M
Revenue / Employee (Annual)$4,400
Pretax Margin (Annual)-39655.50%
Cash / Share (Annual)$0.11
3-Month Return Std Dev141.38%
Net Income / Employee (TTM)$-1,835,600
ROE (Last FY)-58.48%
Net Interest Coverage (Annual)-19.84x
EPS Basic Excl Extra (Annual)$-0.25
Receivables Turnover (TTM)0.05x
Total Debt / Equity (Quarterly)2.55x
EPS Incl Extra (TTM)$-0.26
Receivables Turnover (Annual)0.03x
ROI (TTM)-329.56%
P/S Ratio (TTM)259.90x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.23
Forward P/E4.04x
Price vs S&P 500 (52W)-95.13%
Year-to-Date Return-76.26%
5-Day Price Return-7.74%
EPS Normalized (Annual)$-0.25
ROA (5Y Avg)-1228.96%
Net Profit Margin (Annual)-39655.50%
Month-to-Date Return-5.43%
EBITD / Share (Annual)$-0.26
Operating Margin (Annual)-40865.69%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.26
P/B Ratio (Annual)84.90x
Pretax Margin (TTM)-11463.51%
Book Value / Share (Annual)$0.13
Price vs S&P 500 (13W)-50.61%
Beta2.03x
Revenue / Share (TTM)$0.00
ROE (TTM)-352.06%
52-Week Low$0.17
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
JUNSJupiter Neurosciences, Inc. Common Stock | — | — | D | $0.24 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Jupiter Neurosciences is a clinical-stage biopharmaceutical company developing a resveratrol-based therapeutic platform to address neuroinflammation in central nervous system diseases. Its lead candidate, JOTROL, targets conditions including Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.